Quince Therapeutics, Inc. (QNCX) Fair Value 2026

QNCX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.8 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (43/100)

Quick Summary — As of 2026-08-28, Quince Therapeutics, Inc. (QNCX) trades at $33.75. QOC: 4.8/10. Value Trap Risk: 43/100 (WARN). 1/13 models active.

Key Facts

Ticker
QNCX
Price
$33.75
Quality Score
4.8/10
Value Trap Risk
43/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +228.6% upside with 33% confidence
Risk: Value Trap score of 43 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give QNCX?

1 Intrinsic Value Models vs. Current Price ($33.75)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $110.92 +228.6%

All Models Active

All 1 models are displayed above.

What Is Quince Therapeutics, Inc. (QNCX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Quince Therapeutics, Inc. is potentially undervalued at its current price of $33.75. Based on our 13-model framework, Quince Therapeutics, Inc.'s intrinsic value is estimated at a median fair value of $110.92 — representing +228.6% implied upside — with 1 out of 1 active models confirming this thesis.

What Do the Models Say About QNCX?

1 of 13 models are currently active for QNCX. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does QNCX Rank in Biotechnology?

Among 625 Biotechnology stocks, QNCX ranks #376 by Quality of Company score. CirclFi's QOC score of 4.8/10 evaluates 32 fundamental signals. A score of 4.8 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to biotechnology enterprise businesses. For Quince Therapeutics, Inc., metrics like R&D burn rate provide important context that general-purpose valuation models may underweight.

Is QNCX a Value Trap?

CirclFi's Value Trap algorithm assigns QNCX a score of 43/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Quince Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Quince Therapeutics, Inc. scores 4.8 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every QNCX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across QNCX's 1 active models, average confidence is 33%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Quince Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

TTRXTurn Therapeutics Inc.QOC 4.8LYELLyell Immunopharma, Inc.QOC 4.8CNSYCerenome, Inc.QOC 4.8MLYSMineralys Therapeutics, Inc.QOC 4.8SNGXSoligenix, Inc.QOC 4.8ATOSAtossa Therapeutics, Inc.QOC 4.8OSTXOS Therapies IncorporatedQOC 4.0CSBRChampions Oncology, Inc.QOC 6.8IPHAInnate Pharma S.A.QOC 5.5EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: TTRX · LYEL · CNSY · MLYS · SNGX · ATOS · OSTX · CSBR · IPHA · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to QNCX?

5 companies across all industries closest to QNCX’s Quality of Company score of 4.8/10.

TSATTelesat CorporationQOC 4.8ONMDOneMedNet CorporationQOC 4.8OPTTOcean Power Technologies, Inc.QOC 4.8DFSCDEFSEC Technologies Inc.QOC 4.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: TSAT · ONMD · OPTT · DFSC · NVDA

Where Does QNCX Sit in CirclFi's Biotechnology Rankings?

QNCX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Quince Therapeutics, Inc.’s Valuation?

What is Quince Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Quince Therapeutics, Inc. (QNCX). The Quality of Company score is 4.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is QNCX overvalued or undervalued right now?

At $33.75, 1 of 1 active models suggest QNCX may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Quince Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.8 mean for QNCX?

Quince Therapeutics, Inc.'s QOC of 4.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on QNCX?

CirclFi analyzes QNCX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is QNCX a value trap in 2026?

Quince Therapeutics, Inc.'s Value Trap score is 43/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Quince Therapeutics, Inc. (QNCX) a Quality of Company score of 4.8/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/QNCX/ · Methodology
Primary sources for this QNCX valuation
  • Financial statements: Quince Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001662774) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for QNCX as of ; valuations recomputed .